NCT05285774 (PS100BTCL) is a clinical trial in Mild Brain Traumatic Injury, sponsored by Centre Hospitalier de Douai.

Who is sponsoring NCT05285774?

NCT05285774 is sponsored by Centre Hospitalier de Douai.

What condition does NCT05285774 study?

NCT05285774 studies Mild Brain Traumatic Injury, Compliance, Patient.

Is NCT05285774 still recruiting?

NCT05285774 is currently completed. Last updated 30 August 2023.

Last reviewed 2023-08-30 · How we verify

NCT05285774: PS100BTCL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interest of the S100B Protein Assay in Mild Traumatic Brain Injuries at the DOUAI Hospital

Completed Last updated 30 August 2023

What this trial tests

trial in Mild Brain Traumatic Injury in 258 participants. Completed in 6 August 2023.

Timeline

6 April 2022

Primary endpoint
6 August 2023

6 August 2023

Quick facts

Lead sponsor	Centre Hospitalier de Douai
Status	Completed
Study type	OBSERVATIONAL
Enrollment	258
Start date	6 April 2022
Primary completion	6 August 2023
Estimated completion	6 August 2023
Sites	1 location across France

Conditions studied

Mild Brain Traumatic Injury — all drugs for Mild Brain Traumatic Injury →
Compliance, Patient — all drugs for Compliance, Patient →

Sponsor

Centre Hospitalier de Douai

Who can join

18 and older, any sex, with Mild Brain Traumatic Injury or Compliance, Patient. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective is to evaluate the feasibility and interest of setting up a protocol for the systematic measurement of the S100B protein in patients with mild traumatic brain injury admitted to the emergency room of Douai hospital in order to reduce the number of unnecessary brain scans. The main evaluation criterion is the percentage of patients admitted to the emergency department of Douai hospital for mild traumatic brain injury, whose protocol for the systematic measurement of the S100B protein would make it possible to avoid the realization of a brain scans for patients with a protein assay S100B ≤ 0.10 µg/L, carried out within 3h of the onset of MCT. The systematic dosage of the S100B protein in the context of mild traumatic brain injury still does not appear in the recommendations for good practice in 2021. This study will contribute to the reflection on the use of the S100B protein in the development of new recommendations for good practice of mild traumatic brain injury support.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05285774 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier de Douai
Last refreshed: 30 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05285774.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing